Nordic Nanovector AS – Registered share capital increase
5,000 share options were exercised at a strike price of NOK 6,75 per share under the Company’s share option program. After this option exercise, the total number of options outstanding is 1,080,239.
The share capital increase relating to the issuance of the 5,000 shares has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,298,608.2 divided into 26,493,041 shares, each with a nominal value of NOK 0.2.
INFORMATION
Luigi Costa
Chief Executive Officer
Cell: (+41) 79 12 48 601
E-mail: lcosta@nordicnanovector.com
Tone Kvåle
Chief Financial Officer
Cell: (+47) 91 51 95 76
E-mail: tkvale@nordicnanovector.com
About Nordic Nanovector AS
Nordic Nanovector AS is a privately held company established in 2009. The company is based in Norway and has offices and laboratories in Oslo. The company is developing novel innovative anticancer radioimmunotherapeutics to treat non-Hodgkin Lymphoma (NHL) and other hematological malignancies.
About Betalutin
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of life of people who suffer from non-Hodgkin Lymphoma (NHL).
Tags:
